Cargando…
Case Report: Combined pembrolizumab, 5-fluorouracil, and cisplatin therapy were remarkably effective in p16-positive squamous cell carcinoma of unknown primary
BACKGROUND: Cancer of unknown primary (CUP) is a malignant tumor without a known primary lesion with a frequency of 3−5%. It can be divided into favorable and unfavorable prognosis subsets. While recommended treatments are available for the former group, there is no established treatment for the lat...
Autores principales: | Suzuki, Risako, Hamada, Kazuyuki, Ohkuma, Ryotaro, Homma, Mayumi, Tsurui, Toshiaki, Iriguchi, Nana, Ishiguro, Tomoyuki, Hirasawa, Yuya, Ariizumi, Hirotsugu, Kubota, Yutaro, Horiike, Atsushi, Yoshimura, Kiyoshi, Wada, Satoshi, Yamochi, Toshiko, Tsunoda, Takuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10365966/ https://www.ncbi.nlm.nih.gov/pubmed/37496666 http://dx.doi.org/10.3389/fonc.2023.1231986 |
Ejemplares similares
-
Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy
por: Ohkuma, Ryotaro, et al.
Publicado: (2023) -
A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer: A case report
por: Hamada, Kazuyuki, et al.
Publicado: (2022) -
Novel quantitative immunohistochemical analysis for evaluating PD-L1 expression with phosphor-integrated dots for predicting the efficacy of patients with cancer treated with immune checkpoint inhibitors
por: Ohkuma, Ryotaro, et al.
Publicado: (2023) -
Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 Antibodies
por: Ohkuma, Ryotaro, et al.
Publicado: (2021) -
Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor
por: Hamada, Kazuyuki, et al.
Publicado: (2023)